Peer-reviewed veterinary case report
Serum myeloperoxidase levels in dogs with mitral valve heart failure
By Park, Jong-In et al.·Published in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire·2017·College of Veterinary Medicine and Institute of Veterinary Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of serum myeloperoxidase concentration in dogs with heart failure due to chronic mitral valvular insufficiency.
- Species:
- dog
Plain-English summary
A group of dogs with heart failure caused by chronic mitral valve disease had their blood tested for a specific enzyme called myeloperoxidase (MPO). The study found that dogs with more severe heart failure had lower levels of MPO in their blood. This suggests that measuring MPO could help veterinarians understand how serious a dog's heart condition is. While the relationship wasn't strong, it indicates that as heart failure worsens, MPO levels tend to drop.
People also search for: dog heart failure symptoms · myeloperoxidase levels in dogs · chronic mitral valve disease in dogs
Abstract
Myeloperoxidase (MPO) is a leukocyte-derived enzyme involved in the process of heart failure and is found to have good diagnostic and prognostic values in humans with chronic heart failure. This study evaluated the relationship between serum MPO levels and the severity of heart failure (HF) due to chronic mitral valvular insufficiency (CMVI) in dogs. Eighty-two client-owned dogs consisting of 69 dogs with different stages of HF due to CMVI and 13 age-matched healthy dogs were enrolled in this study. Serum MPO concentrations in the healthy and CMVI groups were determined by enzyme-linked immunosorbent assay (ELISA) using a canine-specific monoclonal anti-MPO antibody. Serum MPO concentrations were 273.3 ± 179.6 ng/L in the controls, 140.8 ± 114.1 ng/L in the International Small Animal Cardiac Health Council (ISACHC) I group, 109.0 ± 85.2 ng/L in the ISACHC II group, and 106.0 ± 42.3 ng/L in the ISACHC III group. Close negative correlation to serum MPO concentration was found in the severity of heart failure (ISACHC stage). Although this study found a modest relationship between serum MPO levels and the severity of HF due to CMVI in dogs, it also suggested that serum MPO levels decreased as the severity of HF increased.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28154461/